After selling failed NASH drug to Ipsen, French startup nabs a liver disease player in small buyout
About two years after Genfit recorded a company-altering flop in NASH, the French biotech’s new vision appears to be coming into sharper focus.
In a small-time buyout, Genfit acquired the Swiss startup Versantis for CHF40 million upfront, or roughly $41.4 million, the companies announced early Monday morning. The deal, which includes another CHF65 million ($67.3 million) in milestones, helps position Genfit better in a separate but related rare liver disease: acute-on-chronic liver failure, or ACLF.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.